Inotiv

Inotiv, Inc.
Company type	Public company
Traded as	Nasdaq: NOTV
Industry	Pharmaceutical industry
Founded	1974 as Bioanalytical Systems
Founder	Peter Kissinger
Headquarters	Lafayette, Indiana, United States
Key people	Robert W. Leasure, Jr., President & CEO; Beth A. Taylor, CFO;
Services	Contract research organization
Revenue	US$572 million (2023);
Operating income	-US$81 million (2023);
Net income	-US$105 million (2023);
Total assets	US$856 million (2023);
Total equity	US$269 million (2023);
Number of employees	1,200+ (2020)
Website	www.inotiv.com
	Footnotes / references;

Inotiv, Inc. is a contract research organization organized in Indiana and headquartered in Lafayette, Indiana. The company operates two core business units: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The CRS business unit offers drug development and environmental sciences services, including safety assessment, analytical, metabolism, CMC and regulatory consultancy for small molecule drug candidates, biotherapeutics, and biomedical devices. The RMS business unit provides research models (live animals), lab animal diets and bedding and support services.

The company has been criticized for its animal testing practices, most specifically animal testing on non-human primates as well as on beagles. It has also been criticized for its laboratory animal sources. In 2022, the United States Department of Agriculture found multiple violations of the Animal Welfare Act of 1966 at the company's dog-breeding facility in Cumberland, Virginia, to which the company pleaded guilty, resulting in $35 million in fines. The company is accredited by AAALAC International.